Alectinib in Resected ALK Positive Non Small Cell Lung Cancer

This phase 3 global trial evaluated adjuvant alectinib versus platinum based chemotherapy in patients with resected ALK positive NSCLC (stage IB–IIIA). Alectinib significantly improved disease free survival, with 93.6% of patients alive and disease free at 2 years compared to 63.7% in the chemotherapy group. The benefit extended to CNS disease free survival, and safety data showed fewer discontinuations due to adverse events. These findings support alectinib as a new standard for adjuvant treatment in this patient population.

This phase 3 global trial evaluated adjuvant alectinib versus platinum based chemotherapy in patients with resected ALK positive NSCLC (stage IB–IIIA). Alectinib significantly improved disease free survival, with 93.6% of patients alive and disease free at 2 years compared to 63.7% in the chemotherapy group. The benefit extended to CNS disease free survival, and safety data showed fewer discontinuations due to adverse events. These findings support alectinib as a new standard for adjuvant treatment in this patient population.